Reported 1 day ago
Precigen Inc. (NASDAQ:PGEN) has seen its stock rise over 300% year-to-date, driven by the FDA's approval of its Papzimeos therapy, the first treatment for adults with recurrent respiratory papillomatosis. Analysts have responded positively, upgrading the stock and highlighting its robust pipeline and market potential, with projected sales reaching $15 million in Q4 2025. Despite growing analyst optimism, some experts suggest that other AI stocks may present even greater opportunities.
Source: YAHOO